← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	NVTA 26 DELISTED Invitae Corporation NVTA	140	+39	+39%	$945M
27	27 CareDx CDNA $3.45B	139	+35	+34%	$870M
28	28 Arrowhead Research ARWR $8.26B	132	+16	+14%	$1.07B
29	29 Vericel Corp VCEL $2.1B	132	+3	+2%	$489M
30	30 Voyager Therapeutics VYGR $127M	119	-6	-5%	$547M
31	31 Pacific Biosciences PACB $609M	118	+19	+19%	$590M
32	32 Fate Therapeutics FATE $231M	116	+13	+13%	$893M
33	33 Atara Biotherapeutics ATRA $96.9M	115	-9	-7%	$1.92B
34	34 Veracyte VCYT $3.57B	111	+36	+48%	$340M
35	35 Lineage Cell Therapeutics LCTX $250M	106	-1	-0.9%	$130M
36	36 Abeona Therapeutics ABEO $266M	104	+12	+13%	$444M
37	37 DELISTED Adverum Biotechnologies ADVM	101	+1	+1%	$269M
38	BLCM 38 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	100	+4	+4%	$150M
39	ATHX 39 DELISTED Athersys, Inc. Common Stock ATHX	99	-5	-5%	$58.2M
40	40 uniQure QURE $1.56B	99	+2	+2%	$822M
41	ADAP 41 DELISTED Adaptimmune Therapeutics ADAP	93	+7	+8%	$888M
42	42 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	92	+13	+16%	$1.06B
43	43 Wave Life Sciences WVE $629M	92	+14	+18%	$1.19B
44	44 Arbutus Biopharma ABUS $850M	88	+17	+24%	$227M
45	NSTG 45 DELISTED NanoString Technologies, Inc. NSTG	87	+6	+7%	$489M
46	46 Rocket Pharmaceuticals RCKT $259M	84	+8	+11%	$906M
47	47 Cellectis CLLS $111M	81	-5	-6%	$325M
48	48 Standard BioTools LAB $258M	79	-5	-6%	$291M
49	49 Solid Biosciences SLDB $615M	76	+12	+19%	$878M
50	ATNX 50 DELISTED Athenex, Inc. Common Stock ATNX	74	+7	+10%	$262M